PMID- 38312545
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240206
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 10
IP  - 2
DP  - 2024 Jan 30
TI  - Study on the mechanism of naringin in promoting bone differentiation: In vitro 
      and in vivo study.
PG  - e24906
LID - 10.1016/j.heliyon.2024.e24906 [doi]
LID - e24906
AB  - OBJECTIVE: Osteoporosis is a common clinical bone disease that occurs most 
      frequently in middle-aged and elderly people. Various traditional herbal medicine 
      formulations have shown significant benefits in models of osteoporosis. In this 
      study, we aim to investigate the osteogenic efficacy of naringin (NRG) in the 
      osteoporotic state. DESIGN: We treated Bone marrow stromal cells (BMSCs) with 
      various concentrations of NRG for 3 and 7 days. BMSC proliferation was measured 
      by the MTT assay. The effect of NRG on the osteogenic differentiation of BMSCs 
      was detected by ALP and alizarin red staining. The effect of NRG on the 
      BMP2/Runx2/Osterix signaling pathway was analyzed by using real-time PCR. The 
      effect of NRG on the oestrogen receptor was measured by Enzyme-linked 
      immunosorbent assay. In vivo animal experiments were performed by micro-computed 
      tomography and ALP immunohistochemistry to determine the ectopic osteogenic 
      effect of NRG sustained-release nanoparticles in a mouse model of osteoporosis. 
      RESULTS: NRG promoted the proliferation and osteogenic differentiation of BMSCs. 
      Moreover, it also activated the BMP2/Runx2/Osterix signaling pathway. When NRG 
      sustained-release nanoparticles were added in vivo in animal experiments, we 
      found that NRG sustained-release nanoparticles had better ectopic osteogenic 
      effects in a mouse model of osteoporosis. CONCLUSIONS: NRG induced osteoblastic 
      differentiation of BMSCs by activating the BMP2/Runx2/Osterix signaling pathway 
      and promoted the regulation of oestrogen receptor pathway protein expression, and 
      NRG sustained-release nanoparticles exerted a more significant in vivo ectopic 
      osteogenic effect in an osteoporosis mouse model. Therefore, naringin is expected 
      to be developed as a novel treatment for inducing osteogenesis, because of its 
      ubiquitous, cost-efficient, and biologically active characteristics. However, 
      further research is needed on how to improve the pharmacokinetic properties of 
      naringin and its specific mechanism.
CI  - (c) 2024 The Authors.
FAU - Li, Xian
AU  - Li X
AD  - Hospital of Stomatology, The First Affiliated Hospital of Jinan University, 
      Guangzhou, China.
FAU - Zhou, Xiaojun
AU  - Zhou X
AD  - School of stomatology, Jinan University, Guangzhou, China.
AD  - Department of Stomatology, The Sixth Affiliated Hospital of Jinan University, 
      Dongguan, China.
FAU - Huang, Zhanyu
AU  - Huang Z
AD  - School of stomatology, Jinan University, Guangzhou, China.
FAU - Chen, Kexiao
AU  - Chen K
AD  - School of stomatology, Jinan University, Guangzhou, China.
FAU - Jiang, Xinrong
AU  - Jiang X
AD  - School of stomatology, Jinan University, Guangzhou, China.
FAU - Lai, Renfa
AU  - Lai R
AD  - Hospital of Stomatology, The First Affiliated Hospital of Jinan University, 
      Guangzhou, China.
FAU - Li, Zejian
AU  - Li Z
AD  - Hospital of Stomatology, The First Affiliated Hospital of Jinan University, 
      Guangzhou, China.
AD  - School of stomatology, Jinan University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20240118
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10834819
OTO - NOTNLM
OT  - BMP2
OT  - BMSCs
OT  - Naringin
OT  - Osteogenesis
OT  - Osteoporotic
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/02/05 06:42
MHDA- 2024/02/05 06:43
PMCR- 2024/01/18
CRDT- 2024/02/05 04:20
PHST- 2023/07/16 00:00 [received]
PHST- 2024/01/16 00:00 [revised]
PHST- 2024/01/17 00:00 [accepted]
PHST- 2024/02/05 06:43 [medline]
PHST- 2024/02/05 06:42 [pubmed]
PHST- 2024/02/05 04:20 [entrez]
PHST- 2024/01/18 00:00 [pmc-release]
AID - S2405-8440(24)00937-X [pii]
AID - e24906 [pii]
AID - 10.1016/j.heliyon.2024.e24906 [doi]
PST - epublish
SO  - Heliyon. 2024 Jan 18;10(2):e24906. doi: 10.1016/j.heliyon.2024.e24906. 
      eCollection 2024 Jan 30.